Eloctate ITI
Phase 3Small molecule
Eloctate ITI is one of 38 small molecule programs targeting Hemophilia. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Hemophilia
#DrugCompanyPhaseTrials
1Crixivan
Merck & Co.Approved
Videx
Bristol-Myers SquibbApproved
Hivid
CConrado Roberto Hoffmann Filho
Approved
Zerit
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Cyklokapron
AAmring
Approved
Daklinza
Bristol-Myers SquibbPhase 3
Recombinant Factor VIII
BayerApproved
Antithrombin Concentrate (ATIIIC)
SanofiApproved
Qfitlia
GGenzyme, a Sanofi Company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Eloctate ITI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMargaret Ragni